In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Unity Biotechnology Inc (UBX), with a price target of $33. The company’s shares opened today at $8.17, close to its 52-week low of $7.39.
According to TipRanks.com, Syed is a 2-star analyst with an average return of 0.2% and a 48.4% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Wave Life Sciences, and Gilead Sciences.
Currently, the analyst consensus on Unity Biotechnology Inc is a Moderate Buy with an average price target of $27.
See today’s analyst top recommended stocks >>
The company has a one-year high of $24.56 and a one-year low of $7.39. Currently, Unity Biotechnology Inc has an average volume of 192.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.
